Emilien Loeuillard

Emilien Loeuillard is a Senior Scientist at NextPoint Therapeutics, Inc. since January 2023, with prior experience as a Research Fellow at the Mayo Clinic from January 2018 to December 2022, specializing in the immunobiology of cholangiocarcinoma and the tumor immune microenvironment. Emilien's postdoctoral research at the Mayo Clinic Division of Gastroenterology and Hepatology involved developing expertise in liver disease and onco-immunology. As a PhD candidate at Inserm from February 2014 to February 2017, Emilien focused on metabolic pathology related to liver conditions at the Saint Antoine Paris research center under the supervision of Chantal Housset. Additional experience includes a master’s internship at Inserm in 2013, studying TGF beta pathway modulation during fibrosis in animal models of inflammatory bowel disease. Emilien's academic background includes a Research Doctorate from Pierre and Marie Curie University and advanced degrees in Physiology and Molecular and Cell Biology from Université de Rouen.